www.innocyto.com.cn

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

Anti-Human DLL3 (Rovalpituzumab Biosimilar)

Catalog Number:	505401, 505402, 505403
Size:	1 mg, 5 mg, 20 mg
Target Name:	DLL3, Delta-like protein 3, SCDO1
Regulatory Status:	RUO

PRODUCT DETAILS

Clone:	Rovalpituzumab
Application:	Flow cytometry, animal model study
Reactivity:	Human
Format:	Liquid
Product Description:	Anti-Human DLL3 (Rovalpituzumab Biosimilar)
Isotype:	Human IgG1
Clonality:	Recombinant
Immunogen:	Human DLL3
Species specificity:	Human
Purity:	>95% by reducing SDS-PAGE
Grade:	In vivo
Storage Conditions:	4ºC
Maximal Shelf Life:	12 months
RRID:	AB_3739330
Antibody Type:	Recombinant
Reactivity:	Human

BACKGROUND INFORMATION

Rovalpituzumab, as a therapeutic, is an antibody–drug conjugate (ADC) consisting of a humanized monoclonal antibody directed against delta-like ligand 3 (DLL3) linked to a potent cytotoxic agent. Structurally, the antibody portion belongs to the immunoglobulin G1 (IgG1) subclass and is composed of two identical heavy chains and two identical light chains connected by disulfide bonds, forming the canonical Y-shaped structure typical of IgG molecules. The antibody backbone, known as SC16, retains full Fc functionality for structural stability and extended systemic half-life through recycling by the neonatal Fc receptor (FcRn). The molecule has an approximate molecular mass of 150 kilodaltons (kDa).

The antigen-binding fragments (Fab) of Rovalpituzumab are derived from murine antibody sequences that confer high-affinity and selective binding to DLL3, an inhibitory ligand within the Notch signaling pathway that is normally expressed at low levels in healthy tissue but can be found on specific cell membranes.